GlassScriptPhysician profile
Larisa Mashensky
NPI 1134181373
$13,756.42
in general payments reported to CMS, 2019-2025
52 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,958 · 2020: $2,896 · 2021: $1,846 · 2022: $1,401 · 2023: $1,226 · 2024: $1,581 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,602 · Education: $54.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,601.88 |
| Education | $54.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,821.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,662.35 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Novo Nordisk INC | $929.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $908.63 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $730.68 | 2019-2025 | Trelegy Ellipta, Nucala |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.33 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $538.55 | 2019-2020 | |
| Pfizer INC. | $526.65 | 2019-2025 | |
| Amarin Pharma, INC. | $506.70 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $486.32 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Lilly USA, LLC | $437.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merz North America, INC. | $391.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $374.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $374.27 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $337.62 | 2019-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Mashensky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.